Journal Information
Vol. 42. Issue. 2.March - April 2022
Pages 113-222
Vol. 42. Issue. 2.March - April 2022
Pages 113-222
Letter to the Editor
Open Access
Peritoneal dialysis in non-renal solid organ transplants, experience in our center
Diálisis peritoneal en trasplantados de órgano sólido no renal: experiencia en nuestro centro
Ana Cristina Andrade López
Corresponding author

Corresponding author.
, José Joaquín Bande Fernández, Carmen Rodríguez Suárez, Elena Astudillo Cortés
Área de Gestión Clínica de Nefrología, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
This item has received

Under a Creative Commons license
Article information
Full Text
Download PDF
Tables (1)
Table 1. Baseline clinical-epidemiological characteristics of non-renal solid organ transplant patients.
Full Text
Dear Editor,

The risk of developing chronic kidney disease five years after a non-renal solid organ transplant varies in the range of 7%–21%.1 The mechanisms involved include chronic dysfunction of the transplanted organ and previous acute kidney injury with incomplete recovery of renal function. However, the most important mechanism continues to be direct nephrotoxicity from calcineurin inhibitors, added to other factors derived from the use of these drugs that contribute to the progression of chronic kidney disease.2–4

It is estimated that 29% of this population will progress to advanced chronic kidney disease and therefore require renal replacement therapy.2,4,5 The use of peritoneal dialysis (PD) has been limited in these patients for fear of a higher incidence of infectious and non-infectious complications due to immunosuppression, and of possible calcineurin inhibitor-related peritoneal toxicity. Such toxicity can cause changes in the morphology of the peritoneal membrane (neoangiogenesis, vascular hyalinosis, profibrotic changes), but without significant repercussions on peritoneal transport (demonstrated only in animal models).4–6

We describe here our centre experience with this group of patients on PD. This was a descriptive observational study that included all patients with a non-renal solid organ transplant who started PD from January 2012 to October 2019. The study group consisted of 10 patients: two liver transplant recipients, one double-lung transplant recipient and seven heart transplant recipients. Their characteristics are shown in Table 1. There were no cases excluded after they started on PD. The patients were referred by the transplant medical team of each speciality to our unit, where they were informed of the different renal replacement therapy techniques, ultimately opting for PD. No routine abdominal imaging tests were performed before starting the PD, although liver transplant patients had already undergone these studies as part of their regular monitoring.

Table 1.

Baseline clinical-epidemiological characteristics of non-renal solid organ transplant patients.

Patient  Charlson  Age, years  Gender  BMI  HTN  DM type 2  Albumin, g/l  CRP, mg/dl  EGFR, ml/min  Residual diuresis, cc  Transplant  IS  Time from transplant-start PD, months  Time on PD, months  PD modality  Kt/V 
67  Male  23  Yes  Yes  33  0.6  1,000  Heart  TC/EVE  55  CAPD  1.3 
53  Male  23  Yes  Yes  39  0.1  1,500  Heart  TC/EVE  74  10  CAPD  1.9 
63  Male  27  No  No  39  1.5  500  Liver  TC  50  26  CAPD  1.7 
72  Male  34  Yes  No  29  0.7  12  1,000  Heart  MMF  228  28  CAPD  1.9 
69  Male  23  Yes  No  38  0.5  600  Heart  TC  46  65  CAPD  2.5 
71  Male  28  Yes  Yes  32  0.4  1,000  Liver  TC  20  29  APD 
72  Male  29  Yes  Yes  33  1.2  16  2,000  Heart  TC/MMF  69  CAPD 
75  Male  28  Yes  Yes  40  10  800  Heart  CisA/MMF  240  14  CAPD  2.1 
42  Male  18  No  No  29  0.4  15  1,000  Heart  TC/MMF  144  CAPD 
10  20  Female  18  Yes  No  41  0.8  1,000  Lung  TC/EVE  180  CAPD 

APD: automated peritoneal dialysis; BMI: body mass index; CAPD: continuous ambulatory peritoneal dialysis; CisA: ciclosporin A; CRP: C-reactive protein; DM: diabetes mellitus; EGFR: estimated glomerular filtration rate; EVE: everolimus; HTN: hypertension; IS: immunosuppression; MMF: mycophenolate mofetil; PD: peritoneal dialysis; TC: tacrolimus.

According to their body mass index, 80% of the patients were of normal weight and 20% low weight; although albumin is not the best marker of nutrition, 30% had baseline hypoalbuminaemia. The mean time between the transplant and the start of PD was 7.2 years (86.4 months). The majority (90%) were taking a calcineurin inhibitor when the PD was started and no significant differences were observed in the pattern of immunosuppression between the different transplanted organs.

With regard to the baseline peritoneal equilibrium test in these patients, 44% were fast transporters, 33% fast average and 11% slow average. There were no significant changes in the peritoneal equilibrium test at one year compared to baseline. We believe that most of these patients are fast transporters due to a more protracted chronic inflammatory state, with increased peritoneal surface area. Although we did not have inflammatory cytokine measurements, we observed a tendency towards having elevated C-reactive protein.

There were no significant differences compared to the rest of the population on PD at our centre (38% fast transporters, 41% fast average, 13% slow average, 1% slow).

Regarding infectious complications, there were four episodes of peritonitis due to Staphylococcus aureus in the same patient and three exit site infections: two due to Staphylococcus aureus and one due to Serratia marcescens. There were no fungal infections. At present, the rate of peritonitis in the PD population at our centre corresponds to a ratio of 0.38 episodes per patient-year, and the ratio in the solid organ transplant group was 0.1 episodes per patient-year, suggesting that there is no direct relationship with immunosuppression.

One heart transplant patient had an inguinoscrotal hernia a month after starting PD, requiring a temporary transfer to haemodialysis; four weeks after the surgical repair, he restarted the technique without incident. There were no other non-infectious complications.

During follow-up, four patients left the programme: two received a kidney transplant; and two died. The causes of death were complications unrelated to the technique.

PD is now considered comparable to haemodialysis in terms of survival, and may even have advantages over haemodialysis due to the better preservation of residual renal function and less haemodynamic stress.3,4 Those factors could even make it particularly indicated in this group of patients, in whom preserving residual renal function can be complicated in clinical practice.

In conclusion, in our experience, with the limitation of the small sample size, patients with non-renal solid organ transplants do well on PD without any added risk of infectious or non-infectious complications, with good outcomes in terms of safety and adequacy of the dialysis, and no differences in peritoneal transport regardless of the transplanted organ.

A.O. Ojo, P.J. Held, F.K. Port, R.A. Wolfe, A.B. Leichtman, E.W. Young, et al.
Chronic renal failure after transplantation of a nonrenal organ.
N Engl J Med., 349 (2003), pp. 931-940
R.D. Bloom, P.P. Reese.
Chronic kidney disease after nonrenal solid-organ transplantation.
J Am Soc Nephrol., 18 (2007), pp. 3031-3041
A. Buffet, S. Guillouët, T. Lobbedez, M. Ficheux, A. Lanot, C. Béchade.
Safety of peritoneal dialysis after nonrenal solid-organ transplantation.
Perit Dial Int., 38 (2018), pp. 37-43
J. Perl, J.M. Bargman, S.V. Jassal.
Peritoneal dialysis after nonrenal solid organ transplantation: clinical outcomes and practical considerations.
Perit Dial Int., 30 (2010), pp. 7-12
T. Cornelis, J.P. Rioux, J.M. Bargman, C.T. Chan.
Home dialysis is a successful strategy in nonrenal solid organ transplant recipients with end-stage renal disease.
Nephrol Dial Transplant., 25 (2010), pp. 3425-3429
R. Van Westrhenen, J. Aten, N. Hajji, O.J. de Boer, S.C. Kunne, D.R. deWaart, et al.
Cyclosporin A induces peritoneal fibrosis and angiogenesis during chronic peritoneal exposure to a glucose-based, lactate-buffered dialysis solution in the rat.
Blood Purif., 25 (2007), pp. 466-472

Please cite this article as: Andrade López AC, Bande Fernández JJ, Rodríguez Suárez C, Astudillo Cortés E. Diálisis peritoneal en trasplantados de órgano sólido no renal: experiencia en nuestro centro. Nefrologia. 2022;42:210–212.

Copyright © 2020. Sociedad Española de Nefrología
Nefrología (English Edition)
Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?